Type to search

Diseases Immunology

Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease

Share
Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease | Pharmtech Focus

Athos Therapeutics, Inc. (“Athos”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today a comprehensive Master Research Agreement for a collaborative project on Inflammatory Bowel Disease (IBD) with Lahey Hospital & Medical Center (“Lahey”). This collaboration will advance systems biology and computational analyses in the field of Inflammatory Bowel Diseases (IBD).

Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples with the following clinical descriptions: Crohn’s disease (CD) active, CD inactive (in remission), Ulcerative colitis (UC) active, UC inactive (in remission), and controls. The results of the biopsy analyses will be correlated with detailed clinical information including the patient’s age, sex, disease location, prior treatments, and status.

“We are excited to collaborate with Dr. Randall Pellish and his team to identify novel molecular targets and subtypes of IBD patients,” said Dimitrios Iliopoulos, PhD, MBA, President & CEO. “Lahey’s IBD patient biomaterials will be fed into our Athos Learning Computational Ensemble

(ALCE) engine to further elucidate the complexity of IBD and the heterogeneity of drug responses.”

“Athos Therapeutics is developing a precision medicine approach to the treatment of IBD and other autoimmune disorders,” said Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO. “The availability of high-quality tissue resources linked to verified clinical data, which forms the basis for our collaboration with Lahey Hospital, will make this possible and allow for the identification of new disease sub-types and for the identification of novel drug targets.”

“We are very excited about our research initiatives with Athos Therapeutics,” said Randall Pellish, MD, Director, Lahey Inflammatory Bowel Disease Center, Division of Gastroenterology, Lahey Hospital and Medical Center. “This collaborative research project will allow us to work on vital questions addressing new ways of classifying and treating inflammatory bowel disease with the goal of developing meaningful, perhaps paradigm shifting, treatment strategies.”

Tags:

Next Up